You just read:

Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor (DENKI) PL265 for the Treatment of Neuropathic Pain

News provided by

Pharmaleads

Jun 29, 2017, 02:00 ET